EP 0726896 A1 19960821 - 5-ARYLISOXAZOL-4-YL-SUBSTITUTED 2-AMINO CARBOXYLIC ACID COMPOUNDS
Title (en)
5-ARYLISOXAZOL-4-YL-SUBSTITUTED 2-AMINO CARBOXYLIC ACID COMPOUNDS
Title (de)
5-ARYLISOXAZOL-4-YL-SUBSTITUIERTE 2-AMINO CARBONSÄUREN
Title (fr)
COMPOSES D'ACIDE 2-AMINOCARBOXYLIQUE SUBSTITUE PAR 5-ARYLISOXAZOL-4-YLE
Publication
Application
Priority
- DK 9400411 W 19941102
- DK 124393 A 19931103
Abstract (en)
[origin: WO9512587A1] 2-Aminocarboxylic acid compounds substituted with 5-arylisoxazol-4-yl or 5-arylisothiazol-4-yl and having general formula (I), wherein A is a bond or a spacer group; B is a group -CH(NR'R'')-COOH wherein R' and R'' are independently hydrogen or C1-6 alkyl, or B is a group of formula (II), wherein R2, R3 and R4 are substituents; or R3 and R4 or R4 and R2 are connected in order to form a ring; E is O, S, COO, (CH2)n-COO, O-(CH2)n-COO or S-(CH2)n-COO wherein n is 1-6, 5-tetrazolyl, 5-tetrazolyl-C1-6 alkyl, 3-hydroxyisoxazolyl or 3-hydroxyisoxazolyl-C1-6 alkyl; D is O or S; and R1 is an optionally substituted aryl or heteroaryl group; are excitatory amino acid receptor ligands useful in the treatment of cerebral ischaemia, Huntington's disease, epileptic disorders, Parkinson's disease, Alzheimer's disease, schizophrenia, pain, depression and anxiety.
IPC 1-7
IPC 8 full level
C07D 275/02 (2006.01); A61K 31/42 (2006.01); A61K 31/422 (2006.01); A61K 31/425 (2006.01); A61K 31/496 (2006.01); A61K 31/505 (2006.01); A61P 9/10 (2006.01); A61P 25/00 (2006.01); A61P 25/08 (2006.01); A61P 25/14 (2006.01); A61P 25/18 (2006.01); A61P 25/24 (2006.01); A61P 25/26 (2006.01); A61P 25/28 (2006.01); C07D 261/10 (2006.01); C07D 261/12 (2006.01); C07D 261/18 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); C07D 417/04 (2006.01)
CPC (source: EP KR)
A61K 31/41 (2013.01 - KR); A61P 9/10 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/08 (2017.12 - EP); A61P 25/14 (2017.12 - EP); A61P 25/18 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 25/26 (2017.12 - EP); A61P 25/28 (2017.12 - EP); C07D 261/12 (2013.01 - EP KR); C07D 261/18 (2013.01 - KR); C07D 413/04 (2013.01 - EP); C07D 413/14 (2013.01 - EP); C07D 417/04 (2013.01 - EP)
Citation (search report)
See references of WO 9512587A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9512587 A1 19950511; AU 680062 B2 19970717; AU 8057994 A 19950523; CA 2175685 A1 19950511; CN 1056837 C 20000927; CN 1136810 A 19961127; CZ 127296 A3 19960911; DK 124393 D0 19931103; EP 0726896 A1 19960821; EP 0994107 A1 20000419; FI 961872 A0 19960502; FI 961872 A 19960503; HU 9601167 D0 19960729; HU T74692 A 19970128; JP H09504531 A 19970506; KR 960705797 A 19961108; NO 306159 B1 19990927; NO 961783 D0 19960502; NO 961783 L 19960625; NZ 275088 A 19970822; PL 314182 A1 19960902; RU 2138488 C1 19990927; SK 56496 A3 19961204; ZA 948631 B 19950710
DOCDB simple family (application)
DK 9400411 W 19941102; AU 8057994 A 19941102; CA 2175685 A 19941102; CN 94194388 A 19941102; CZ 127296 A 19941102; DK 124393 A 19931103; EP 94931523 A 19941102; EP 99125828 A 19941102; FI 961872 A 19960502; HU 9601167 A 19941102; JP 51297095 A 19941102; KR 19960702307 A 19960503; NO 961783 A 19960502; NZ 27508894 A 19941102; PL 31418294 A 19941102; RU 96112168 A 19941102; SK 56496 A 19941102; ZA 948631 A 19941102